Chronic or delayed treatment with an oral dithiocarbamate analog decreases glycation and protects diabetic arteries.

Article Details

Citation
Copy to clipboard

Pieper GM, Siebeneich W, Olds CL, Lai CS

Chronic or delayed treatment with an oral dithiocarbamate analog decreases glycation and protects diabetic arteries.

Eur J Pharmacol. 2003 Jul 4;472(1-2):127-34.

PubMed ID
12860481 [ View in PubMed
]
Abstract

In the present study, we examined the efficacy of a dithiocarbamate-based compound, denoted as NOX-700, on diabetes-induced endothelial dysfunction and glycosylation of hemoglobin (Hb). Streptozotocin-induced diabetic rats received 3 mg/ml NOX-700 in drinking water beginning at 72 h or 4 weeks and continued to 8 weeks. Oxidative and glycooxidative stress were examined by electrophoretic mobility shift assay (EMSA) for nuclear factor-kappaB (NF-kappaB) in nuclear fractions of aortic homogenates and by glycosylated Hb, respectively. Vascular reactivity was examined in aortic ring segments ex vivo. Treatment with NOX-700 inhibited glycosylated Hb formation when given long-term or after delayed administration. NOX-700 improved endothelium-dependent relaxation to acetylcholine but did not alter reactivity to norepinephrine or nitroglycerin, suggesting selective protection of the endothelium. Nuclear factor-kappaB (NF-kappaB) nuclear binding activity was significantly increased in diabetic aortas and abrogated by NOX-700. Thus, vascular protection by NOX-700 is believed to be mediated, in part, by an antioxidant mechanism and decreased protein glycation.

DrugBank Data that Cites this Article

Drugs